Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.14B 169M 147M 137M 125M 237M 16.11B 240M 1.61B 632M 8.02B 634M 620M 26.9B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 918M 136M 118M 110M 101M 191M 12.97B 194M 1.3B 509M 6.46B 510M 499M 21.65B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.32%
Yield 2024 *
-
Yield 2025 -
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
20/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
18/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
03/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
29/10/24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/10/24 Rightongene Biotechnology's Chairman, Vice General Managers Arrested for Fraud Suspicion; Shares Down 4% MT
1 day+2.28%
1 week+10.30%
1 month-2.82%
3 months-30.01%
6 months-30.88%
Current year-21.59%
1 week 18.4
Extreme 18.4
20.66
1 month 17.81
Extreme 17.81
23.34
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
36
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 22/07/2024
Director of Finance/CFO 34 27/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 22/07/2024
Director/Board Member 41 13/05/2019
Director/Board Member 53 24/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.28%+10.30%-31.91%-45.96% 169M
+6.33%+9.95%+291.09%+326.35% 21.74B
-3.83%-1.14%-44.32%-27.66% 9.38B
-1.35%-4.94%+41.19%+19.19% 6.49B
-4.37%+2.16%+261.39%-24.06% 6B
-1.81%-0.93%-11.76%-13.45% 5.57B
-2.61%+0.97%-44.12% - 4.43B
+4.21%+7.67%-16.64%-27.25% 4.38B
+9.99%+1.30%+74.78%+93.55% 4.25B
-1.02%+5.24%-17.29%-39.41% 2.8B
Average +0.78%+2.08%+50.24%+29.03% 6.52B
Weighted average by Cap. +1.59%+3.43%+117.76%+113.54%

Financials

2024 2025
Net sales 242M 35.87M 31.18M 29.02M 26.65M 50.32M 3.42B 51.1M 342M 134M 1.7B 135M 132M 5.72B 177M 26.24M 22.81M 21.23M 19.49M 36.81M 2.51B 37.38M 250M 98.23M 1.25B 98.56M 96.39M 4.18B
Net income -15.76M -2.33M -2.03M -1.89M -1.73M -3.27M -223M -3.32M -22.26M -8.74M -111M -8.76M -8.57M -372M -50.38M -7.46M -6.48M -6.03M -5.54M -10.46M -712M -10.62M -71.13M -27.92M -354M -28.01M -27.39M -1.19B
Net Debt -210M -31.13M -27.06M -25.19M -23.13M -43.68M -2.97B -44.35M -297M -117M -1.48B -117M -114M -4.96B -223M -32.94M -28.64M -26.65M -24.47M -46.21M -3.14B -46.93M -314M -123M -1.57B -124M -121M -5.25B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
336
Date Price Change Volume
31/07/26 CN¥20.66 +2.28% 797,011
30/07/26 CN¥20.20 +0.15% 956,607
29/07/26 CN¥20.17 +4.02% 1,086,583
28/07/26 CN¥19.39 -0.67% 856,390
27/07/26 CN¥19.52 +4.22% 986,985

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock